Glaukos Corporation

DB:6GJ Stock Report

Market Cap: €8.1b

Glaukos Valuation

Is 6GJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6GJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6GJ (€143) is trading below our estimate of fair value (€307.52)

Significantly Below Fair Value: 6GJ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6GJ?

Key metric: As 6GJ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6GJ. This is calculated by dividing 6GJ's market cap by their current revenue.
What is 6GJ's PS Ratio?
PS Ratio22.9x
SalesUS$360.35m
Market CapUS$8.26b

Price to Sales Ratio vs Peers

How does 6GJ's PS Ratio compare to its peers?

The above table shows the PS ratio for 6GJ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2x
AFX Carl Zeiss Meditec
2x6.4%€4.1b
SHL Siemens Healthineers
2.6x5.7%€57.3b
EUZ Eckert & Ziegler
3.3x5.4%€918.5m
DRW3 Drägerwerk KGaA
0.3x3.8%€801.6m
6GJ Glaukos
22.9x20.4%€8.3b

Price-To-Sales vs Peers: 6GJ is expensive based on its Price-To-Sales Ratio (22.9x) compared to the peer average (2x).

Price to Sales Ratio vs Industry

How does 6GJ's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.3x3.8%US$822.20m
PHH2 Paul Hartmann
0.3xn/aUS$801.91m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
6GJ 22.9xIndustry Avg. 3.5xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 6GJ is expensive based on its Price-To-Sales Ratio (22.9x) compared to the European Medical Equipment industry average (3.6x).

Price to Sales Ratio vs Fair Ratio

What is 6GJ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6GJ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio22.9x
Fair PS Ratio9.2x

Price-To-Sales vs Fair Ratio: 6GJ is expensive based on its Price-To-Sales Ratio (22.9x) compared to the estimated Fair Price-To-Sales Ratio (9.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6GJ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€143.00
€147.98
+3.5%
10.7%€177.86€115.37n/a12
Dec ’25€133.00
€135.94
+2.2%
9.3%€154.63€109.77n/a12
Nov ’25€120.00
€127.12
+5.9%
8.8%€143.34€106.35n/a11
Oct ’25€115.00
€122.69
+6.7%
7.6%€134.50€103.81n/a11
Sep ’25€118.00
€121.53
+3.0%
7.3%€134.06€103.47n/a12
Aug ’25€104.00
€123.64
+18.9%
6.6%€134.37€106.57n/a12
Jul ’25€109.00
€109.86
+0.8%
9.1%€122.66€93.63n/a12
Jun ’25€101.00
€104.73
+3.7%
7.9%€120.13€92.41n/a12
May ’25€89.50
€99.48
+11.2%
8.7%€112.24€78.57n/a12
Apr ’25€84.50
€96.18
+13.8%
9.9%€110.80€77.56n/a12
Mar ’25€81.00
€95.26
+17.6%
8.9%€106.27€77.62n/a12
Feb ’25€81.50
€84.60
+3.8%
12.9%€101.33€59.88n/a12
Jan ’25€71.50
€79.30
+10.9%
11.3%€95.34€59.02€143.0012
Dec ’24€58.00
€76.22
+31.4%
10.1%€84.66€60.08€133.0011
Nov ’24€63.50
€78.12
+23.0%
10.1%€85.17€64.35€120.009
Oct ’24€71.50
€77.77
+8.8%
9.9%€86.93€63.56€115.0010
Sep ’24€69.00
€75.76
+9.8%
9.6%€82.25€62.15€118.0010
Aug ’24€70.00
€69.39
-0.9%
17.3%€81.85€45.47€104.0010
Jul ’24€65.50
€58.85
-10.2%
15.1%€73.45€45.91€109.0010
Jun ’24€52.50
€53.14
+1.2%
13.6%€65.50€40.59€101.0010
May ’24€43.00
€51.23
+19.1%
12.5%€62.89€40.11€89.5010
Apr ’24€46.00
€52.64
+14.4%
13.1%€65.09€41.51€84.5010
Mar ’24€44.20
€52.64
+19.1%
13.1%€65.09€41.51€81.0010
Feb ’24€44.60
€52.18
+17.0%
15.5%€62.58€38.65€81.5010
Jan ’24€39.60
€54.11
+36.6%
15.9%€64.10€39.59€71.5010

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 15:44
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Glaukos Corporation is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Ravi MisraBerenberg
Joanne WuenschBMO Capital Markets Equity Research